an advocacy tool: untangling the web of antiretroviral price reductions
DESCRIPTION
An advocacy tool: Untangling the Web of Antiretroviral Price Reductions. Arax Bozadjian HIV Focused Pharmacist Access Campaign for Essential Medicines. History: Widely varying prices between on patent and off-patent medicines - PowerPoint PPT PresentationTRANSCRIPT
Washington D.C., USA, 22-27 July 2012www.aids2012.org
An advocacy tool: Untangling the Web of Antiretroviral Price
Reductions
Arax BozadjianHIV Focused Pharmacist
Access Campaign for Essential Medicines
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Untangling the Web: 15th edition• History:
Widely varying prices between on patent and off-patent medicines
1998 Thai NGO campaign for generic fluconazole sees price drop 97% in nine months
• Annual publication since 2000: provides ARV pricing in response to lack of transparent and reliable information Comprehensive pricing
information provided by originator and generic manufacturers of ARVs
Source of price comparison, patent information, access issues
• Used as advocacy tool; quoted in publications
• Available online: http://utw.msfaccess.org
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Purpose and Methodology• Purpose: Help purchasers make informed decisions
when purchasing ARVs for use in developing countries; used as an advocacy tool
• How: Details originator and generic company prices of individual ARVs; analyzes price evolution
• Methodology: – Questionnaire sent to companies (voluntary)– Information requested: ARV prices for developing
countries; restrictions that apply to quoted prices – Generic manufacturers with at least one ARV WHO
PQ are invited to participate• Limitation:
– No commitment from manufacturer
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Practical use of UTW as a Tool
• Increased Transparency of pricing and access policies
• UTW provides both price and patent information
• Market segmentation by innovator companies• Advantages of generic competition (first and
second line ARVs)• Historical data
Washington D.C., USA, 22-27 July 2012www.aids2012.org
First, Second and Third Line ARV prices at present
• The price of a third line regimen is 14 x more expensive than the most affordable first line regimen and over 6 x more than the most affordable second line regimen
Washington D.C., USA, 22-27 July 2012www.aids2012.org
First Line Regimen:TDF/3TC/EFV
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Second Line Regimen: ATV/r
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Third Line Regimen: Darunavir
Washington D.C., USA, 22-27 July 2012www.aids2012.org
Questions and/or comments?
Thank You;Arax Bozadjian